IMBRUVICA® (ibrutinib) Patient Support Resources IMBRUVICA® (ibrutinib) Patient Support Resources

Discover a world of support

Connect to personalized IMBRUVICA® (ibrutinib) support: access, affordability, and nurse call support and resources.

We provide personalized assistance to help you through your IMBRUVICA® treatment journey by:

  • Contacting your insurance provider to help you understand your coverage

  • Finding affordability options to help you afford your treatment

  • Providing educational resources about your disease

  • Offering nurse call support that answers your questions and provides information about IMBRUVICA® and your disease

Want to receive support as you start you new treatment?

It's easy to get started

1-877-877-3536 Monday-Friday, 8AM-8PM ET

One-on-one support that simplifies access to IMBRUVICA® (ibrutinib)

We offer one-on-one support to help you learn about access to IMBRUVICA® by:

  • Helping you understand your insurance coverage

  • Coordinating timely IMBRUVICA® delivery

Regardless of insurance type, we can help you understand your options

For patients with commercial insurance

YOU&i™ Instant Savings Program:
If you are eligible and have commercial health insurance, you pay no more than $10 per month* for IMBRUVICA®

*Month refers to a 30-day supply subject to maximum benefit based on 12 monthly fills. Eligible patients may qualify for instant savings on their commercial insurance co-pay, deductible, and coinsurance medication costs for IMBRUVICA®. Not valid for federal and state healthcare program beneficiaries. Not valid for patients enrolled in Medicare or Medicaid.

For patients with federally funded Medicare, Medicaid, or commercial insurance

Foundation support may be available

Patient Access Network Foundation
1-866-316-PANF (7263)

Leukemia & Lymphoma Society

Other resources:

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is committed to providing access to medicines for uninsured individuals who lack the financial resources to pay for them. If your patient needs IMBRUVICA® (ibrutinib), and is uninsured and unable to pay for their medicine, please have them contact a JJPAF program specialist at 1-800-652-6227, 9:00AM to 6:00PM ET, or visit the foundation website at to see if they might qualify for assistance.

YOU&i™ nurses are here to answer your questions

Our YOU&i™ nurses and resources can answer your questions about IMBRUVICA® and your disease

  • Ongoing calls with your YOU&i™ nurse scheduled at a time convenient for you

  • Ongoing educational materials sent to your email or home address

  • Patient Starter Kits for new IMBRUVICA® patients

Topics may include:

  • How to talk to loved ones

  • Understanding your disease

  • What you need to know about IMBRUVICA®

  • Making the most out of your doctor visits

  • Tips on how to take your medication on time

  • Speaking up about what matters to you about your care

  • Sticking with your treatment plan and not giving up

  • Learning about being a caregiver

  • Stories of others with the same disease


You are now leaving

By clicking "OK" below you will be taken to a website that may contain links or references to other websites to which our Privacy Policy may not apply. We encourage you to read the Privacy Policy of every website you visit.

For any questions about the Pharmacyclics Privacy Policy, please visit


Are you a healthcare professional?

You are leaving the patient and caregiver site and entering the US Healthcare professional site. The information contained in this site is intended for US healthcare professionals only. Click “OK” below if you are a healthcare professional.



What should I tell my healthcare provider before taking IMBRUVICA®?

Before you take IMBRUVICA®, tell your healthcare provider about all of your medical conditions, including if you:

  • Have had recent surgery or plan to have surgery. Your healthcare provider may stop IMBRUVICA® for any planned medical, surgical, or dental procedure
  • Have bleeding problems
  • Have or had heart rhythm problems, smoke, or have a medical condition that increases your risk of heart disease, such as high blood pressure, high cholesterol, or diabetes
  • Have an infection
  • Have liver problems
  • Are pregnant or plan to become pregnant. IMBRUVICA® can harm your unborn baby. If you are able to become pregnant, your healthcare provider will do a pregnancy test before starting treatment with IMBRUVICA®
    • Females should not become pregnant during treatment and for 1 month after the last dose of IMBRUVICA®
    • Males should avoid getting female partners pregnant during treatment and for 1 month after the last dose of IMBRUVICA®
  • Are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will take IMBRUVICA® or breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking IMBRUVICA® with certain other medicines may affect how IMBRUVICA® works and can cause side effects.

How should I take IMBRUVICA®?

  • Take IMBRUVICA® exactly as your healthcare provider tells you to take it
  • Take IMBRUVICA® 1 time a day
  • Swallow IMBRUVICA® capsules whole with a glass of water. Do not open, break, or chew IMBRUVICA® capsules
  • Take IMBRUVICA® at about the same time each day
  • If you miss a dose of IMBRUVICA® take it as soon as you remember on the same day. Take your next dose of IMBRUVICA® at your regular time on the next day. Do not take 2 doses of IMBRUVICA® on the same day to make up for a missed dose
  • If you take too much IMBRUVICA®, call your healthcare provider or go to the nearest hospital emergency room right away

What should I avoid while taking IMBRUVICA®?

  • You should not drink grapefruit juice, eat grapefruit, or eat Seville oranges (often used in marmalades) during treatment with IMBRUVICA®. These products may increase the amount of IMBRUVICA® in your blood

What are the possible side effects of IMBRUVICA®?

IMBRUVICA® may cause serious side effects, including:

  • Bleeding problems are common during treatment with IMBRUVICA® that can be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs of bleeding, including: blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding or bleeding that is severe or that you cannot control, vomit blood or vomit looks like coffee grounds, cough up blood or blood clots, increased bruising, dizziness, weakness, confusion, change in your speech, or a headache that lasts a long time
  • Infections can happen during treatment with IMBRUVICA®. These infections can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, weakness, confusion, or other signs or symptoms of an infection during treatment with IMBRUVICA®
  • Decrease in blood cell counts. Decreased blood counts (white blood cells, platelets, and red blood cells) are common with IMBRUVICA®, but can also be severe. Your healthcare provider should do monthly blood tests to check your blood counts
  • Heart rhythm problems (atrial fibrillation and atrial flutter). Heart rhythm problems have happened in people treated with IMBRUVICA®, especially in people who have an increased risk for heart disease, have an infection, or who have had heart rhythm problems in the past. Tell your healthcare provider if you get any symptoms of heart rhythm problems, such as feeling as if your heart is beating fast and irregular, lightheadedness, dizziness, shortness of breath, chest discomfort, or you faint
  • High blood pressure (hypertension). New or worsening high blood pressure has happened in people treated with IMBRUVICA®. Your healthcare provider may start you on blood pressure medicine or change current medicines to treat your blood pressure
  • Second primary cancers. New cancers have happened in people who have been treated with IMBRUVICA®, including cancers of the skin or other organs
  • Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS

The most common side effects of IMBRUVICA® include: diarrhea, muscle and bone pain, rash, nausea, bruising, tiredness, and fever.

Diarrhea is a common side effect in people who take IMBRUVICA®. Drink plenty of fluids during treatment with IMBRUVICA® to help reduce your risk of losing too much fluid (dehydration) due to diarrhea. Tell your healthcare provider if you have diarrhea that does not go away.

General information about the safe and effective use of IMBRUVICA®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IMBRUVICA® for a condition for which it was not prescribed. Do not give IMBRUVICA® to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IMBRUVICA® that is written for health professionals.

These are not all the possible side effects of IMBRUVICA®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please review the full Important Product Information.


What is IMBRUVICA® (ibrutinib)?

IMBRUVICA® (ibrutinib) is a prescription medicine used to treat people with:

  • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
  • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion
  • Waldenström's macroglobulinemia (WM)
  • Mantle cell lymphoma (MCL) who have received at least one prior treatment
  • Marginal zone lymphoma (MZL) who require a medicine by mouth or injection (systemic therapy) and have received a certain type of prior treatment
    • For MCL and MZL, IMBRUVICA® is approved on response. Data are not yet available to show if IMBRUVICA® improves survival or symptoms

It is not known if IMBRUVICA® is safe and effective in children.

Your use of the information on this site is subject to the terms of the Legal Notice and Privacy Policy of Pharmacyclics LLC. This site is published by Pharmacyclics LLC which has developed the content in conjunction with Janssen Biotech, Inc. Any information that is collected on this site may be shared between Pharmacyclics LLC and Janssen Biotech, Inc. This information is intended for use by our customers, patients, and healthcare professionals in the United States only. Pharmacyclics LLC recognizes that the Internet is a global communication medium; however laws, regulatory requirements, and medical practices vary from country to country.

IMBRUVICA® (ibrutinib) capsules are covered by U.S. Pat. Nos. 7,514,444; 8,008,309; 8,497,277; 8,476,284; 8,697,711 and 8,703,780.

© Pharmacyclics LLC. 2017

© Janssen Biotech, Inc. 2017

03/17 PRC-02718